Critical Contrast: Bluejay Diagnostics (NASDAQ:BJDX) and Apyx Medical (NASDAQ:APYX)

Apyx Medical (NASDAQ:APYX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Apyx Medical and Bluejay Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-58.59%	-137.98%	-36.74%
Bluejay Diagnostics	N/A	-155.67%	-117.82%

Risk & Volatility

Apyx Medical has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Institutional and Insider Ownership

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 16.8% of Apyx Medical shares are held by company insiders. Comparatively, 0.4% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Apyx Medical and Bluejay Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$48.10 million	0.78	-$18.71 million	($0.67)	-1.48
Bluejay Diagnostics	$250,000.00	7.81	-$9.95 million	($1,372.00)	0.00

Bluejay Diagnostics has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Apyx Medical and Bluejay Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	0	2	0	1	2.67
Bluejay Diagnostics	0	0	0	0	0.00

Summary

Apyx Medical beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.